Journal
Targeted Oncology
Publication Date
5-1-2024
Volume
19
Issue
3
First Page
321
Last Page
332
Document Type
Open Access Publication
DOI
10.1007/s11523-024-01054-z
Rights and Permissions
Maris, M., Salles, G., Kim, W.S. et al. ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. Targ Oncol 19, 321–332 (2024). https://doi.org/10.1007/s11523-024-01054-z This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Maris, Michael; Abboud, Camille N; and et al., "ASCT2-targeting antibody-drug conjugate MEDI7247 in adult patients with relapsed/refractory hematological malignancies: A first-in-human, phase 1 study." Targeted Oncology. 19, 3. 321 - 332. (2024).
https://digitalcommons.wustl.edu/oa_4/5671
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
